Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Integrase Inhibitors | 1 | 2018 | 165 | 0.520 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 285 | 0.490 |
Why?
|
| HIV Infections | 5 | 2024 | 17346 | 0.210 |
Why?
|
| Mass Screening | 4 | 2024 | 5428 | 0.210 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 3200 | 0.160 |
Why?
|
| Immunization Programs | 1 | 2020 | 268 | 0.150 |
Why?
|
| Models, Theoretical | 2 | 2020 | 3577 | 0.140 |
Why?
|
| Oxazines | 1 | 2018 | 349 | 0.130 |
Why?
|
| Universities | 1 | 2020 | 994 | 0.120 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 559 | 0.120 |
Why?
|
| Home Care Services | 1 | 2021 | 648 | 0.120 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 849 | 0.110 |
Why?
|
| Food, Fortified | 1 | 2015 | 189 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 5492 | 0.110 |
Why?
|
| Pyridones | 1 | 2018 | 808 | 0.100 |
Why?
|
| Occupational Diseases | 1 | 2020 | 1491 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2019 | 832 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 2206 | 0.090 |
Why?
|
| Basic Reproduction Number | 2 | 2020 | 36 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2928 | 0.090 |
Why?
|
| Drug Costs | 1 | 2018 | 1183 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2019 | 6236 | 0.080 |
Why?
|
| Vaccination | 1 | 2020 | 3381 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2023 | 3800 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 1998 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2015 | 1994 | 0.070 |
Why?
|
| Piperazines | 1 | 2018 | 2519 | 0.070 |
Why?
|
| Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8635 | 0.070 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 1782 | 0.060 |
Why?
|
| South Africa | 2 | 2022 | 1841 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2019 | 5078 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5334 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3080 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2015 | 3413 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 3204 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 743 | 0.050 |
Why?
|
| Sick Leave | 1 | 2021 | 105 | 0.040 |
Why?
|
| Patient Isolation | 1 | 2020 | 100 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 23981 | 0.040 |
Why?
|
| Heart Failure | 1 | 2023 | 11672 | 0.040 |
Why?
|
| Malawi | 1 | 2019 | 304 | 0.040 |
Why?
|
| Efficiency | 1 | 2021 | 476 | 0.040 |
Why?
|
| Aftercare | 1 | 2023 | 913 | 0.030 |
Why?
|
| Alkynes | 1 | 2017 | 320 | 0.030 |
Why?
|
| Sputum | 1 | 2019 | 506 | 0.030 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 330 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2017 | 432 | 0.030 |
Why?
|
| Benzoxazines | 1 | 2017 | 316 | 0.030 |
Why?
|
| Anti-HIV Agents | 2 | 2024 | 4524 | 0.030 |
Why?
|
| Humans | 13 | 2024 | 761326 | 0.030 |
Why?
|
| Financing, Personal | 1 | 2017 | 309 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 12144 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 289 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2017 | 621 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 10203 | 0.030 |
Why?
|
| Health Education | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Disease Progression | 2 | 2021 | 13500 | 0.030 |
Why?
|
| Female | 7 | 2022 | 392485 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1665 | 0.030 |
Why?
|
| United States | 4 | 2021 | 72317 | 0.020 |
Why?
|
| Adult | 4 | 2020 | 221122 | 0.020 |
Why?
|
| Inpatients | 1 | 2023 | 2548 | 0.020 |
Why?
|
| Pregnant Women | 1 | 2015 | 566 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1332 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3438 | 0.020 |
Why?
|
| Public Health | 1 | 2023 | 2667 | 0.020 |
Why?
|
| Male | 4 | 2021 | 360621 | 0.020 |
Why?
|
| Malnutrition | 1 | 2015 | 644 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2023 | 3267 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2015 | 2696 | 0.020 |
Why?
|
| Mortality | 1 | 2019 | 2898 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2020 | 41440 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2015 | 1358 | 0.020 |
Why?
|
| Middle Aged | 2 | 2019 | 220774 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 1896 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2019 | 2016 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 5841 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 14665 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2015 | 3025 | 0.010 |
Why?
|
| Hypertension | 1 | 2024 | 8539 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 20092 | 0.010 |
Why?
|
| Time Factors | 1 | 2021 | 39974 | 0.010 |
Why?
|
| Hospitalization | 1 | 2019 | 10715 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 15499 | 0.010 |
Why?
|
| Algorithms | 1 | 2017 | 14025 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2022 | 64645 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39108 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 29858 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 74152 | 0.010 |
Why?
|
Concepts
(90)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(19)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_